Cargando…
miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
BACKGROUND: Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma. Here, we explored the role of miRNAs in melanoma acquired resistance to BRAFi. METHODS: miRNA expression in two BRAF-mutant melanom...
Autores principales: | Caporali, Simona, Amaro, Adriana, Levati, Lauretta, Alvino, Ester, Lacal, Pedro Miguel, Mastroeni, Simona, Ruffini, Federica, Bonmassar, Laura, Antonini Cappellini, Gian Carlo, Felli, Nadia, Carè, Alessandra, Pfeffer, Ulrich, D’Atri, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588909/ https://www.ncbi.nlm.nih.gov/pubmed/31227006 http://dx.doi.org/10.1186/s13046-019-1238-4 |
Ejemplares similares
-
Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017) -
Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015) -
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
por: Levati, Lauretta, et al.
Publicado: (2022) -
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015) -
Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)